USANew treatments and approvals
Accelerated approval for pariglasgene brecaparvovec, first gene therapy for GSD type Ia
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia. The drug is for patients aged 8 years and older. It is used in addition to dietary treatment. The aim is to reduce the daily need for cornstarch. It is the first approved treatment that targets the underlying genetic cause of the disease. Additional study results will be needed for full approval.
What does it mean for patients and families?
A promising step for patients who control their blood sugar with starch day and night. But it does not replace dietary treatment. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
BioPharm International · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Glycogen storage disease type Ia
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.